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doi:10.1016/j.ejvs.2009.02.009Abstract Objectives: The administration of unfractionated heparin (UFH) prior to carotid
clamping during carotid endarterectomy (CEA) transiently increases the platelet aggregation
response to arachidonic acid (AA) despite the use of aspirin. We hypothesized that this
phenomenon might be reduced by using low molecular weight heparin (LMWH) resulting in
fewer emboli in the early post-operative period.
Methods: 183 aspirinated patients undergoing CEA were randomised to 5000 IU UFH (nZ 91) or
2500 IU LMWH (dalteparin, nZ 92) prior to carotid clamping. End-points were: transcranial
Doppler (TCD) measurement of embolisation, effect on bleeding and platelet aggregation to
AA and adenosine 50-diphosphate (ADP).
Results: Patients randomised to UFH had twice the odds of experiencing a higher number of
emboli in the first 3 h after CEA, than those randomised to LMWH (pZ 0.04). This was not asso-
ciated with increased bleeding (mean time from flow restoration to operation end: 23 min
(UFH) vs. 24 min (LMWH), pZ 0.18). Platelet aggregation to AA increased significantly
following heparinisation, but was unaffected by heparin type (pZ 0.90). The platelets of
patients randomised to LMWH exhibited significantly lower aggregation to ADP compared to
UFH (p< 0.0001).
Conclusions: Intravenous LMWH is associated with a significant reduction in post-operative em-
bolisation without increased bleeding. The higher rate of embolisation seen with UFH may be
mediated by increased platelet aggregation to ADP, rather than to AA.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.6 252 3252; fax: þ44 116 252 3179.
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The causes of stroke after carotid endarterectomy (CEA)
are multifactorial.1,2 Intra-operative stroke (i.e. apparent
upon recovery from anaesthesia) tends to follow inadver-
tent technical error (haemodynamic failure, intra-opera-
tive embolisation).3 Post-operative stroke can follow either
hyperperfusion or haemorrhage, but the most common
cause is early post-operative carotid thrombosis (POCT).2,3
POCT was previously thought to be unpredictable and
unpreventable. However, it is now generally accepted that
stroke due to POCT is preceded by 1e2 h of increasing
embolisation.4,5 This reliable forecaster of cerebral
ischaemia can be diagnosed using transcranial Doppler
(TCD) and progression onto stroke can be prevented by the
use of an incremental dose of Dextran.6
Notwithstanding this ability to recognise and then
intervene in high risk patients for POCT, it would clearly be
preferable to determine whether any ‘patient factor’
mediated the susceptibility to early thrombosis. Previous
work from this unit has shown that the platelets of patients
with higher rates of post-operative embolisation were more
sensitive to stimulation by adenosine 5’-diphosphate
(ADP).7 A subsequent randomised trial showed that the
magnitude of post-operative embolisation after CEA was
significantly reduced in patients randomised to 75 mg clo-
pidogrel the night before surgery (in addition to their
normal aspirin).8 However, an unexpected finding from that
study was that immediately following administration of
unfractionated heparin (UFH), and prior to carotid clamp-
ing, platelet aggregation to arachidonic acid (AA) increased
tenfold despite all of the patients being on aspirin.9,10 This
was not related to the known enhancing effects of UFH on
the platelet response to ADP and collagen10 and is clearly
counter-intuitive to classical teaching regarding the irre-
versible effect of aspirin on the cyclo-oxygenase pathway.11
Low molecular weight heparin (LMWH) has a number of
pharmacological advantages over UFH, some of which are
directly influenced by its shorter chain length.12e14 The
rationale underlying the current study was that, since it is
recognised that a number of platelet responses was
affected less with LMWH than with UFH,12,13 the use of
LMWH might be associated with less platelet activation by
AA (following heparin administration) and, consequently,
fewer emboli in the early post-operative period.
Materials and Methods
Study design
Approval was granted from the Local Research Ethics
Committee for a double-blinded randomised controlled trial
in consecutive patients scheduled for CEA at the Leicester
Royal Infirmary, UK. Patients gave their written informed
consent, and all received 75 mg daily aspirin for at least
2 weeks prior to surgery. At commencement of the trial,
computer-generated randomisation of treatment method
(LMWH vs. UFH) were consecutively numbered and sealed in
opaque envelopes. Starting with envelope number one,
these were allocated on a consecutive basis immediately
following induction of anaesthesia. Prior to carotid clampingpatients were anticoagulated either in our standard fashion,
with 5000 IU UFH (Multiparin, CP Pharmaceuticals, Wrex-
ham, UK) or with 2500 IU dalteparin sodium (Fragmin, Pfizer,
New York, USA) intravenously. Because our usual practice is
to anticoagulate with a standard, patient-independent dose
of UFH, we aimed to use an equally effective, universal dose
of LMWH, as suggested by the drug’s manufacturers.
Exclusion criteria included: refusal to give consent;
aspirin intolerance; absence of a transcranial window for
TCD monitoring; patients on other anticoagulants or anti-
platelet agents within 14 days pre-operatively (heparin,
warfarin, dipyridamole or clopidogrel). Consequently, all
individuals undergoing ‘‘urgent’’ carotid endarterectomy
were excluded, since our practice is to manage these
patients with a continuous intravenous infusion of unfrac-
tionated heparin until surgery. Power calculations were
performed based on previous studies, which suggested that
randomizing 180 patients would enable an 80% chance of
detecting a 20% difference in embolisation between the
two groups and that a 20% difference in platelet response
would be seen in 48 patients (24 in each group).
Blood collection
Blood samples were taken at four time-points: at induction
of general anaesthesia; then at 3, 120 and 330 min
following systemic heparinisation. All blood samples were
taken from an indwelling arterial line into vacutainer tubes
(Becton Dickinson, Oxford, UK), with the first 3 ml of blood
taken into EDTA (0.184 M) and used to obtain a full blood
count (ACT Diff Analyser, Coulter Electronics Ltd, Luton,
UK), and subsequent samples were taken into 0.105 M
buffered sodium citrate solution for immediate processing
for platelet aggregometry.
Platelet aggregometry
Based on a power calculation, ex vivo platelet aggregometry
was performed in the last 65 patients recruited (32 patients in
the LMWH group; 33 patients in the UFH group). Platelet-rich
plasmawaspreparedbycentrifugationof thecitratedsamples
at 150g for 20 min. Born-type aggregometry10 was used to
assessplateletaggregation in response toahighconcentration
of AA (4 103 mol/L; Sigma, Poole, Dorset, UK) and an
intermediate concentration of ADP (3 106 mol/L;
Sigma, Poole, Dorset, UK) using a PAP4 aggregometer (BioData
Corp, Horsham, USA). The concentrations of agonists were
chosen fromprevious titrations, andwere designed to test the
efficacy of the patients’ aspirinisation (with maximal AA) and
the variation in the patients’ platelets’ response to ADP.
Aggregationwasperformedover a10-minperiodand recorded
as the percentage of maximal aggregation compared to
autologous, platelet poor plasma. Where technical failure of
platelet aggregometry occurred (8 instances across the four
AA-mediated aggregometry time-points; 12 in the ADP-
mediated aggregometry) the results were not plotted.
Operation and intra-operative monitoring
All patients underwent a standardized CEA with the use of
normotensive, normocarbic general anaesthesia, and the
Figure 1 Study design and recruitment and breakdown of
patients.
Table 1 Demographic breakdown of trial patients.
Variable N UFH 91 LMWH 92 p value
Age/years 67 10.3 70 8.3 0.13
Sex
Male 70 (77%) 69 (75%) 0.76
Female 21 (23%) 23 (25%)
Weight/kg 76 12.7 80 14.2 0.64
Hypertension 69 (76%) 75 (82%) 0.35
Diabetes 14 (15%) 22 (24%) 0.15
Current smoker 20 (22%) 25 (27%) 0.41
Presentation
Asymptomatic 17 (19%) 13 (14%) 0.41
Stroke 24 (28%) 24 (26%) 0.97
TIA 34 (37%) 43 (47%) 0.20
Amaurosis fugax 16 (18%) 12 (13%) 0.40
Mean carotid stenosis/% 77 8 80 8 0.29
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There were six consultant surgeons either performing the
CEA or supervising a trainee. Independent pharmacists
dispensed either 5000 IU UFH or 2500 IU LMWH, and
systemic heparinisation was administered intravenously by
the anaesthetist 4 min prior to carotid clamping and
insertion of the shunt. The surgeon was blinded to the
type of heparin used. Continuous TCD monitoring of the
blood flow velocity in the ipsilateral middle cerebral
artery was performed for the duration of the operation.
All TCD waveform data were stored on digital audiotape
for blinded offline analysis by the same vascular techni-
cian. Post-operative embolisation was quantified with the
use of standardized consensus criteria.15 The carotid
arteriotomy was closed with a Dacron patch (W. L. Gore,
Flagstaff, Arizona, USA) in all cases, and completion
angioscopy was performed in patients prior to restoration
of flow.1
Post-operative monitoring
All patients were monitored for 3 h post-operatively with
TCD. Using pre-existing Unit criteria, any patient with more
than 25 emboli in a 10 min period was given a 30 ml intra-
venous bolus of Dextran-40 (Pharmacia Ltd, Milton Keynes,
United Kingdom), followed by an infusion starting at 20 ml/h
and then systematically increased until the rate of
embolisation diminished. Thereafter Dextran was
continued for 12 h.
Bleeding tendency
The time from restoration of blood flow to removal of the
surgical drapes was used to estimate the time required to
secure haemostasis, and acted as a surrogate measure of
excess bleeding.
Statistical analysis
Discrete data were analyzed using SPSS version 14.0.0 for
Windows (SPSS Inc., Chicago, Illinois, USA) with the use of
contingency tables (Fisher’s exact test), and continuous
data were analyzed with the use of a 2-tailed Manne
Whitney U test. Data are presented as mean SD. Proba-
bility values <0.05 were considered statistically significant.
Whilst 50% of patients will have one or more emboli
detected in the early post-operative period, only 5% will
develop sustained embolisation,16 making meaningful
statistical analysis difficult. In order to be able to demon-
strate a difference between the two groups, as in previous
work,8 an arbitrary distinction between ‘‘low embolisa-
tion’’ and ‘‘high embolisation’’ was used, in this case the
upper quartile (11 emboli).
Results
Epidemiology
Of the 229 patients undergoing CEA during the study period 46
(21%)wereexcluded (Fig. 1).The183 (79%) remainingpatientswere randomised to either LMWH (nZ 92) or UFH (nZ 91).
The two groups were demographically matched (Table 1).
Post-operative embolisation
The mean number of post-operative emboli was 12 in the
LMWH group, vs. 18 in the UFH group (pZ 0.247), but
patients randomised to UFH were found to be twice as
likely to be ‘‘higher’’ embolisers (29 of 91; 31.9%) than
those randomised to LMWH (17 of 92; 18.5%) (Fig. 2b). This
equates to an odds ratio of 2.06; 95% CI, 1.04e4.10;
pZ 0.0418, Fisher’s exact test. Fig. 2 illustrates the total
number of patients in each group, showing the proportion
experiencing ‘‘high embolisation’’ (shaded bars).
Two patients (2.2%) in the LMWH group received Dextran
therapy to control high-grade embolisation, whereas four
Figure 2 Proportion of patients randomized to 5000 IU UFH
or 2500 IU LMWH intravenously prior to carotid clamping
experiencing post-operative high-rate embolisation (shaded
bars), compared to those who did not (open bars) (pZ 0.04).
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(p> 0.05).
Perioperative haemostatic function
One (1.1%) patient in each group required re-exploration
for post-operative bleeding. The length of time taken from
flow restoration to skin closure was used as an indirect
marker of haemostasis, and was not significantly different
between the two groups: the median time from restora-
tion of flow to removal of the drapes was 23 8.5 min in
the LMWH group and 24 7.5 min in the UFH group
(pZ 0.18).
Perioperative morbidity and mortality
The 30-day disabling stroke or death rate was 2.2%
(2 patients) in both the LMWH and UFH groups. One patient
in the UFH group suffered an acute, intra-operative carotid
artery dissection and a second patient died following
a post-operative intra-cerebral haemorrhage, likely related
to post-operative hyperperfusion on post-operative day 11.
In the LMWH group, one patient suffered an intra-operative
stroke due to embolic occlusion of the ipsilateral middle
cerebral artery following shunt insertion. The second
patient died following a myocardial infarction on post-
operative day 5. None of these patients experienced high
embolisation post-operatively. Complications were evenly
distributed amongst the six consultant surgeons.
Ex vivo platelet aggregation
At induction of anaesthesia, prior to heparin, platelet
aggregation to AA (4 103 mol/L) was less than 20% of
maximum in 50/65 (77%) patients, indicating adequateaspirinisation. Seven patients in the LMWH group and 8
(24%) patients in the UFH group were still responsive to AA
(range 22.1%e90.3%), suggestive of ‘‘aspirin failure’’17 and
were subsequently excluded from the analysis of the
platelet response to AA. The level of aggregation in
response to AA prior to heparin in the remaining 50 patients
was similar in both groups (8.3 4.2% for LMWH vs.
8.7 4.4% for UFH; pZ 0.66) (Fig. 3).
Three minutes after the administration of heparin, the
platelet response to AA increased dramatically (six to
seven-fold) to 56.9 28.2% in the LMWH group (p< 0.0001)
and to 57.6 26.8% in the UFH group (p< 0.0001).
However, this increase was not significantly different
between the two heparin groups (pZ 0.75). The platelet
response to AA subsequently fell so that by 120 min it was
38.3 32.4% in the LMWH group and 27.3 26.1% in the
UFH group (pZ 0.46), and at 330 min was 29.4 31.6% and
21.4 20.7% in the LMWH and UFH groups respectively
(pZ 0.81). This fall in the AA response occurred without
further aspirin therapy.9,10
Fig. 4 shows platelet aggregation in response to ADP at
a concentration of 3 106 mol/L for all 65 subjects. At
induction of anaesthesia, the mean platelet response was
similar in both groups (27.8 13.1% in the LMWH group and
31.7 12.2% in the UFH group (pZ 0.10)). Three minutes
after the administration of heparin, aggregation in response
to ADP increased to 44.1 16.4% in the LMWH group
(p< 0.0001). The increase observed in the UFH group was
even greater, rising to 63.3 11.6% (p< 0.0001). By
120 min the platelet response to ADP had fallen slightly in
both groups but remained significantly greater in patients
randomised to UFH (48.6 15.0%) compared to the LMWH
group (40.0 14.4%; pZ 0.02). At 330 min the UFH group
still showed greater aggregation to ADP (45.1 15.3%)
compared to the LMWH group (37.4 15.2%), which
remained statistically significant (pZ 0.04).Discussion
These findings confirm our previous observations, that
systemic heparinisation causes a transient increase in ex
vivo platelet aggregation in response to AA, despite
adequate aspirinisation.9,10 We have extended these labo-
ratory observations to a randomised clinical study and
shown a potential clinical benefit of LMWH compared to
UFH in terms of reduced POCT.
Post-operative embolisation has a well-proven relation-
ship to post-operative cerebral ischaemic events, and has
been shown to be an effective surrogate outcome measure
for stroke risk.4,5 By using this surrogate end-point we were
able to show a significant effect of the different heparins
on a smaller cohort than would be required using the clin-
ical end-point of stroke.
The thromboembolic material that leads to POCT is
invariably platelet-rich.1,2 However, while antiplatelet
therapy has been shown to reduce the risk of post-opera-
tive stroke,18 embolisation does still occur despite
adequate aspirin therapy.7 In this study we have shown that
LMWH produced a lower level of POCT than UFH, which
raises the question of why LMWH appears to have a benefi-
cial effect.
Figure 3 Platelet aggregation in response to 4 103 mol/L arachidonic acid in 50 patients undergoing CEA. Closed circles;
LMWH group (nZ 25); open circles; UFH group (nZ 25), horizontal bar represents mean ( SD). 15 patients who exhibited greater
than 20% platelet aggregation to AA at induction have been excluded.
LMWH vs. UFH During Carotid Endarterectomy 637The success of vascular reconstruction has relied upon the
anticoagulant properties of heparin since the inception of
these techniques,19 and intravenous UFH has traditionally
been the drug of choice for the prevention of arterial
thromboembolic events. Compared with UFH, LMWH is
considered to induce a more stable and predictable antico-
agulant dose response, and to have a greater ratio of anti-
factor Xa activity to anti-factor IIa activity, which reduces
the generation and activation of thrombin.20 In addition to
reducing the incidence of venous thromboembolism,21 LMWHFigure 4 Platelet aggregation in response to 3 106 mol/L a
circles; LMWH group (nZ 32); open circles; UFH group (nZ 33), hhas previously been shown to be effective in preventing
arterial thrombosis,22 and the findings of this study support
this in a group of patients with carotid artery disease.
However, it is known that while heparin inhibits the
enzymic effects of thrombin, including thrombin-induced
platelet aggregation, it paradoxically potentiates platelet
aggregation induced by a range of platelet agonists,
including ADP, TRAP, PAF and epinephrine.12,23e25 The
binding of heparin to platelets is known to increase with
increasing molecular weight,26 and LMWH is less effectivedenosine diphosphate in 65 patients undergoing CEA. Closed
orizontal bar represents mean ( SD).
638 G.S. McMahon et al.than UFH in inducing several pathways of platelet activa-
tion.12,13,27 Here we reproduced our earlier observations of
a transient failure of aspirin therapy immediately following
systemic heparinisation. As before,9,10 this was seen in
patients who had been adequately aspirinated and was
therefore unrelated to ‘‘aspirin resistance’’. As previously
described, the inhibitory effect of aspirin was subsequently
regained by the patients’ platelets over a few hours,
without any further therapy. Since the major antith-
rombotic effect of aspirin is irreversible, via the acetylation
of platelet cyclo-oxygenase-1 which inhibits thromboxane
A2 synthesis,
11 and since platelets do not possess a nucleus
from which to synthesize new COX-1, this recovery is not
attributable to restoration of COX-1 activity in the plate-
lets. However, although systemic heparinisation resulted in
a significant increase in the ex vivo platelet aggregation
response to AA, there was no significant difference in this
increased response between heparin types, despite the
observed benefit in embolic signals in the patients. The
mechanism and clinical significance underlying this
heparin-induced increase in platelet aggregation to AA
remain to be resolved.
In contrast, although we observed no significant differ-
ence between the effects of UFH and LMWH on AA-induced
platelet aggregation, we found that the platelets of
patients receiving UFH were significantly more responsive
to ADP-induced aggregation than the patients who received
LMWH. Importantly, this difference persisted into the
immediate post-operative period, with the platelets of the
patients in the UFH group remaining significantly more
responsive to ADP-induced aggregation 330 min following
heparinisation. This difference may, in part, explain the
difference observed in post-operative embolisation, and is
compatible with our previous observation that the response
to ADP is a significant predictor of embolisation risk.7
The implementation of effective monitoring and quality-
control techniques4 has corresponded with a decline in
intra-operative stroke rates,28 and a re-evaluation of the
pre-eminence of ‘‘technical error’’ as the cause of CEA-
related stroke.2 The importance of patient-specific factors
in POCT is increasingly recognised.7,29,30 Studies from this
unit have shown that patients undergoing CEA have
a ‘‘thromboembolic potential’’, which remains stable over
time and is predictable pre-operatively by the ex vivo
platelet response to ADP stimulation.7,29 Furthermore, we
have demonstrated that preoperative platelet ADP-inhibi-
tion with clopidogrel significantly reduces post-operative
embolisation.8 Following completion of the current trial, all
patients undergoing CEA in our unit now are given a single
75 mg dose of clopidogrel the night before surgery.
It could be argued that a weight-adjusted dosing of the
heparins may have provided a more reliably standardized
anticoagulation, and that the patients’ response could have
been formally assessed. Nonetheless, although a relatively
small sample size, both heparin regimes provided adequate
anticoagulation at the time of carotid clamping, evidenced
by the absence of proximal carotid thromboses. However, it
is accepted that our findingsmayhave beenpartly influenced
by differences in the pharmacological effects of the two
heparins, aside fromtheir impact onplatelet responsiveness.
In conclusion, this study has shown that intra-operative
anticoagulation with LMWH (2500 IU dalteparin) rather thanUFH (5000 IU heparin) was associated with a significant
(twofold) reduction in higher rate embolisation following
CEA, without an increase in bleeding. Somewhat surpris-
ingly heparin type did not influence the immediate and
transient ex vivo increase in platelet aggregation to AA.
While further studies are required to establish the mecha-
nism and clinical significance of heparin’s effect on the
platelet aggregation to AA, this study has further under-
lined the potential value of targeted ADP-inhibition in
patients undergoing CEA. Whilst LMWH is not currently
licensed for intravenous use in this setting, the results of
this study would support its further evaluation as an
alternative, and perhaps superior, anticoagulant for inva-
sive vascular procedures.
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